TIME reports on evidence along the Thai-Cambodia border that the malaria parasite is gaining resistance to artemisinin â€“ “the only remaining effective drug in the world’s arsenal against malaria’s most deadly strain.”
During its recent board meeting in Addis Ababa, Ethiopia, the Global Fund to Fight AIDS, Tuberculosis and Malaria approved $2.4 billion for the three diseases, PlusNews reports. The money is for the fund’s “ninth round of grants, bringing the total amount of approved funding since its inception in 2001 to $18.4 billion,” according to the publication.
According to a report (.pdf) by Save the Children, climate change is the biggest global health threat to children in the 21st century, the Hindu reports.
In a session at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, experts discussed the tools required to eradicate the disease and highlighted insecticide and drug resistance in some parts of the world, Xinhua reports.
“Two years after some $22 million in donor funds were pumped into malaria control along the Cambodia-Thailand border to fight off suspected resistance to treatment, health workers say the battle is not over,” IRIN reports, adding, “The government reported 103,000 malaria infections and 151 deaths nationwide in 2010. A year later, 85,000 reported infections led to 93 deaths — a 38-percent decline in mortality.” “‘If you take your foot off the â€¦ [accelerator] we can lose everything we have done in the past two to three years,’ Steven Bjorge, anti-malaria team leader in Cambodia for the [WHO], told IRIN in February 2012,” the news service writes.
Pacific Standard magazine examines efforts by researchers around the globe to biologically modify bugs to fight human diseases, such as dengue fever. “Biologically altering bugs isn’t entirely new; it’s been done for nearly half a century to protect crops. … It’s only recently, however, that scientists have begun experimenting with using this technology to combat human diseases,” the magazine writes, adding, “If they succeed, they could create an entirely new way of stopping not only dengue but other insect-borne scourges, such as yellow fever, West Nile virus, and malaria. And stopping these diseases has never been more urgent.”
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto’s Munk School of Global Affairs, writes that, “for the second year in a row, the amount of attention devoted to global health” at the annual G8 summit, which took place at Camp David in Maryland in May, has declined. “Global health was not completely absent from the summit,” she continues, highlighting several health initiatives discussed at the meeting, including the New Alliance for Food Security and Nutrition, launched “to accelerate the flow of private capital to African agriculture” with an aim of “lift[ing] 50 million people out of poverty over the next decade.”
Reuters examines how the fight against malaria in Africa is helping to fuel the continent’s economic growth. “The number of malaria deaths has fallen dramatically in the last decade due to increased aid spending on basic items such as insecticide-treated bed nets and drugs, the World Health Organization (WHO) says,” the news agency writes, noting that an experimental vaccine from GlaxoSmithKline is showing prospect. The news agency discusses the efforts of AngloGold Ashanti, the world’s third largest gold producer, to prevent and treat malaria among its workers, which “‘made economic sense because of the absenteeism and the cost of medication,’ said Steve Knowles, the head of AngloGold’s anti-malaria operations.”
“Pre-emptive treatment of children living in regions where [malaria] is prevalent only during the rainy season could avert 11 million cases and 50,000 deaths a year,” the journal Nature reports, adding, “The estimates are based on the world’s first guidance on seasonal malaria chemoprevention, issued by the World Health Organization (WHO) in March.” “‘One-size-fits-all policies, like bed nets, are great,’ explains Rob Newman, director of the WHO’s Global Malaria Programme in Geneva,” Nature writes. “But for policies with a number of requirements, we need these sorts of analyses to help policymakers chart the path forward,” he added, according to the journal. “Researchers think that parts of Senegal, Burkina Faso, Mali and Niger will emerge [as] the most promising candidates for seasonal chemoprevention according to three factors: malaria burden, predicted malaria seasonality and the efficacy of the drug combination sulphadoxine, pyrimethamine and amodiaquine (SP-AQ),” Nature adds (Maxmen, 6/6).
More Affordable Bednets, Increased Transparency In Market Will Save $22M, UNICEF Executive Director Says
UNICEF Executive Director Anthony Lake said Wednesday “that a more transparent and competitive market will lead to savings of more than $20 million over the next 12 months through a price reduction of 20 percent for bednets that protect people from malaria,” a UNICEF press release reports, noting, “The price of an insecticide-treated, long-lasting bednet has dropped to under $3” (6/6). “‘Never before have bednets been as accessible and affordable for children and families in developing countries,’ said the Director of UNICEF’s Supply Division in Copenhagen, Shanelle Hall, adding that the price reduction is the result of a long-term strategy to create a healthy global market for bednets,” the U.N. News Centre writes (6/6).